A109 PREGNANCY OUTCOMES IN WOMEN EXPOSED TO USTEKINUMAB IN THE CROHN’S DISEASE CLINICAL DEVELOPMENT PROGRAM

BACKGROUND: Ustekinumab (UST) has been approved for moderate to severe Crohn’s Disease (CD) in adult patients (pts). While no adverse developmental outcomes (pre-& postnatal) were observed in animal studies of UST, limited data exist, including previously reported outcomes in psoriasis (PsO) pts...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Can Assoc Gastroenterol
Hlavní autoři: Scherl, E, Jacobstein, D, Murphy, C, Ott, E, Gasink, C, Baumgart, D C, Abraham, B
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2018
Témata:
Paper Sessions
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6508401/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jcag/gwy009.109
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky